Stephen Betschel, Karen Binkley, Rozita Borici-Mazi, Hugo Chapdelaine, Jacques Hébert, Amin Kanani, Paul Keith, Gina Lacuesta, Susan Waserman, William Yang, Valerie Palda, Kelly Lang‐Robertson, Emel Aygören-Pürsün, Aleena Banerji, Jonathan A. Bernstein, Teresa Caballero, Henriette Farkas, Anete S. Grumach, Michihiro Hide, Connie Katelaris, Hilary J. Longhurst, Markus Magerl, Marc Riedl, Andrea Zanichelli, Bruce L. Zuraw, Adil Adatia, Jean-Nicolas Boursiquot, Lori J. Connors, Victoria E. Cook, Michelle Cooper, Lisa Fu, Parwinder Gill, Dawn Goodyear, Amanda Jagdis, Samira Jeimy, Chrystyna Kalicinsky, Palinder Kamra, Manstein Kan, Harold J. Kim, Benoît Laramée, Erika Lee, Eric Leith, Louis Marois, Christine McCusker, Andrew O’Keefe, Ibraheem Othman, Man-Chiu Poon, Charles St-Pierre, Peter Stepaniuk, Ellie Tsai, Kelsey Uminski
This update to the 2019 Canadian Hereditary Angioedema (HAE) Guideline broadens its focus to include the management of patients with HAE worldwide, building on its established international framework. It has been developed through a collaboration of Canadian and international HAE experts and patient groups, coordinated by the Canadian Hereditary Angioedema Network. The objective is to provide evidence-based recommendations, using the Grading of Recommendations Assessment, Development and Evaluation system, for the management of patients with HAE. These include recommendations for the treatment of attacks, short-term prophylaxis, and long-term prophylaxis, as well as recommendations for self-administration, individualized therapy, health-related quality of life, and comprehensive care. New to the 2024 edition are specific recommendations for the treatment of angioedema attacks in individuals with HAE who are breastfeeding/lactating, as well as a dedicated section on shared decision-making. HAE results in spontaneous and often unpredictable attacks of painful swelling, typically affecting the extremities, bowel mucosa, genitals, face, and upper airway. These attacks are associated with significant functional impairment, reduced health-related quality of life, and in the case of laryngeal attacks, a high risk of mortality. Managing HAE is complex, and patient care in Canada, similar to many other countries, remains inconsistent and suboptimal. Care delivery lags behind nations that have implemented more structured management models for HAE, and offer broader access to a wider range of approved therapies. This guideline is intended to be used to optimize HAE management, highlight the importance of individualized care, and provide guidance to healthcare providers, policymakers, patients, and advocates. Primary target users include healthcare providers who are managing patients with HAE, as well as emergency and intensive care physicians, primary care physicians, gastroenterologists, dentists, otolaryngologists, pediatricians, hematologists, dermatologists, and gynecologists who will encounter patients with HAE and need to be aware of this condition. Hospital administrators, insurers and policy makers may also find this guideline helpful.